Novo Nordisk's new Wegovy weight-loss pill records over 3,000 prescriptions in its first four days, signaling strong market entry as competition with Eli Lilly intensifies in the booming obesity treatment sector.
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.
